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With the discussion paper from the ongoing Review of Pharmacy Remuneration and 
Regulation still open for public input, there is an opportunity to reflect on how the services 
currently delivered by community-based pharmacies in Australia can be improved. 
Some of the questions up for discussion concern the ways in which pharmacists and patients 
navigate pharmacists’ dual roles as retailers and dispensers. 
In the post below, bioethicists Wendy Lipworth, Christopher Mayes and Ian Kerridge discuss 
what is at stake when therapeutic and commercial boundaries are blurred, and deliver a 
warning to other health professionals who might consider the addition of merchandising to 
their professional portfolios. 
 
Dr Wendy Lipworth, Dr Christopher Mayes and Professor Ian Kerridge 
write: 
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A national Review of Pharmacy Remuneration and Regulation is currently underway. The 
review, initiated by Federal Health Minister Susan Ley and led by Productivity 
Commissioner, Professor Stephen King, is part of the of Sixth Community Pharmacy 
Agreement between the Commonwealth and the Pharmacy Guild of Australia. 
Balancing activities and roles 
In July this year, the Review panel released a Discussion Paper, asking stakeholders to 
consider a wide range of issues affecting the community pharmacy sector in Australia. 
Among these, stakeholders were asked to reflect upon whether there should be limits to 
pharmacists’ retail or “front of shop” (as distinct from dispensing) activities and whether 
Government funding should take this balance into account. 
Underpinning these questions were concerns about “the possible conflict of interest between 
the ‘retail’ and ‘health care’ environment” (page 25), the “tension between treating 
consumers as customers or patients” (page 47), and whether “the ‘retail environment’ within 
which community pharmacy operates detract(s) from health care objectives” (page 47). 
More specific concerns were raised about the revenue generated from the sale of over-the-
counter (OTC) medicines and complementary products. It was noted that many of these 
products “do not have evidence-based health benefits” and that their sale in a pharmacy 
setting “may misinform consumers of their effectiveness and undermine the professional 
integrity of community pharmacists”(page 47). 
In response, George Tambassis, National President of the Pharmacy Guild of Australia, was 
quoted in the Sydney Morning Herald as saying that attempts to limit or otherwise 
disincentivise front of shop activities were simply ideologically-driven, and would dismantle 
a good system—which he defined on the basis of positive customer satisfaction surveys and 
the high level of trust in pharmacy professionals. 
Professional standing, public good 
We believe that Tambassis is wrong on a number of counts. First, simply labelling an 
argument as “ideological” is not a sufficient basis for its refutation. Indeed, complaints that 
arguments are “ideological” are usually themselves ideological. Second, the fact that there are 
high levels of trust in a particular professional group does not mean that the trust is informed 
or valid (i.e. reflective of the fact that pharmacists genuinely have their customers’ best 
interests at heart) – or that this trust cannot be eroded. Third, while customer satisfaction may 
be a valid measure of commercial or professional transactions, these ratings do not 
necessarily reflect the quality of professional care or the impact of transactions on health and 
wellbeing. 
The fundamental error that Tambassis makes is that he fails to understand the moral anxiety 
that underpins the questions posed in the Discussion Paper—that commercial activities of 
pharmacists and pharmacies might ultimately undermine both their professional standing and 
their contribution to public goods. (1) 
Professionals are thought to possess skills that carry with them moral duties that go beyond 
economic transactions. As a result, relationships between professionals and those to whom 
they have a duty are expected to be based on trust and fidelity, as opposed to an economic 
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exchange between a customer and provider.(2) In the case of health care, the professional 
duty is towards patients and the public, and the concern—expressed implicitly in the 
discussion paper—is that private economic interest will skew and undermine these duties. 
While this may not lead to the unravelling of society (as Emile Durkheim argued in the 
1890s(3)), the erosion of trust in health care professionals is likely to have impacts on patient 
wellbeing and public health that may well not show up in ‘customer satisfaction surveys’. 
Lessons for the medical profession 
It would be easy for doctors reading about the Pharmacy Remuneration and Regulation 
Review to feel morally superior to pharmacists, and not vulnerable to the same criticisms. 
From classical times, doctors have made an effort to distinguish themselves from other health 
professionals by emphasising their episteme and ethics—i.e. their understanding of illness 
and commitment to patient care. While doctors have always sold their services, in general it 
has been other professional groups, most notably apothecaries, who have manufactured and 
sold medical products. 
Over the past 50 years, however, this separation has become progressively eroded as doctors 
now frequently engage with, and benefit financially from, their interactions with industry in 
both research and clinical settings. The most obvious example of this—and the one that has 
attracted the greatest attention—is the relationships that medical professionals have with the 
pharmaceutical industry. Another example is the growing number of doctors practicing 
“integrative medicine”, some of whom also sell supplements and various other kinds of 
complementary and alternative medicines (CAMs). 
It is difficult to demonstrate conclusively that patients are harmed by doctors who have 
financial interests in pharmaceutical companies or CAM products; for this, we have to rely on 
a body of indirect evidence that doctors and researchers who interact with industry 
demonstrate attitudes and behaviours that are not always in the best interests of patients or the 
public. 
The same is not, however, true of the increasing number of doctors manufacturing, selling 
and administering unproven stem cell “therapies” for conditions as diverse as osteoarthritis, 
cerebral palsy, multiple sclerosis, and dementia. This point needs no justification beyond the 
recent case of Sheila Drysdale, an Australian woman who died from bleeding associated with 
a liposuction procedure that was being undertaken solely in order to extract stem cells to 
“treat” her dementia. 
None of this is meant to demonise doctors who earn a living, who innovate, and who interact 
(in limited ways) with health-related industries (to do so would be simply play into George 
Tambassis’s point about “ideology”). However, we do believe that the medical profession 
needs to take seriously the inevitable conflict of interest that occurs in the context of medical 
merchandising. 
The debate about pharmacists’ professional roles and responsibilities should prompt doctors 
to look closely at at the ways in which the boundaries between profiting from time, skills and 
services, and profiting from products, are currently being blurred. 
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